[8]. Robert A Byrne, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Aug 25;ehad191. [9]. Nikolaus Marx, et al. 2023 ESC Guidelines for the management of cardi...
•Coordinator of the EAS Lipid Clinics Network and Co-Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias and lipid consensus papers. •In March 2021 he received from the Presiden...
[11].Byrne, Robert A et al. “2023 ESC Guidelines for the management of acute coronary syndromes.” European heart journal vol. 44,38 (2023): 3720-3826. [12].Comparison Of An “Inclisiran First” Strategy With Usual Care In Patients With Atherosclerotic Cardiovascular Disease: Results From ...
•Coordinator of the EAS Lipid Clinics Network and Co-Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias and lipid consensus papers. •In March 2021 he received from the President of the Republic the honour Commendatore of the Italian ...
3.Mach F,Baigent C,Catapano AL,et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk.Eur Heart J，2020,41(1):111-188. 4.Newman CB,Preiss D,Tobert JA,et al.Statin Safety and Associated Adverse Events:A Scientific Statement From ...
8月27日,欧洲心脏病学会(ESC)和欧洲动脉硬化学会(EAS)联合发布血脂异常管理指南,同时全文刊登在Eur Heart J上。 在欧洲每年有400万人死于心血管病,而80%是可通过管理危险因素可以预防的。“血脂异常就是心血管病最重要的危险因素之一,而且其中低密度脂蛋白胆固醇(LDL-C)与心血管病间的因果关系已经很明确。血脂水平...
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.[8]王昱渊,黎子微,崔鹏辉,武军铎.新型降脂药物的研究进展[J].中国循证心血管医学杂志,2022,14(9):1148-1150.[9]Ray KK, Wright RS, Kallend D,et ...
This article reviews why LDL-C remains overlooked and underestimated despite numerous studies that have proved its role.Recently published EAS/ESC Guidelines for dyslipidemia and EAS Guidelines for prevention set new targets for LDL-C levels in primary and secondary prevention of ASCVD. These ...
[9] Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS guidelines for the management of dysli...
For patients at very-high risk of cardiovascular (CV) events, the 2016 ESC/EAS dyslipidaemia guidelines recommended lipid-lowering therapy (LLT) to achieve an LDL-C level below 70 mg/dL. This was lowered to an LDL-C level below 55 mg/dL in the 2019 guidelines. PURPOSE. To assess: 1)...